Skip to main navigation

Investors
News
- News Releases
- News and Mentions
Presentations & Events
- Presentations
- Events
Stock Performance
- Stock Information
- Analyst Coverage
Financials & Filings
- SEC Filings
- Quarterly Results
Corporate Governance
Resources

News Releases

Year

Nov 27 / 23

Belite Bio, Inc. to Present at the Ophthalmology Innovation Summit (OIS)

Nov 20 / 23

Belite Bio to Participate in the BTIG Ophthalmology Day

Nov 15 / 23

Belite Bio Receives Approval to Initiate Tinlarebant Phase 3 Clinical Trial for GA in the UK

Nov 13 / 23

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Nov 07 / 23

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

Nov 06 / 23

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

Oct 27 / 23

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

Oct 17 / 23

Belite Bio Announces NMPA Submission for Tinlarebant Phase 3 GA Clinical Trial in China

Oct 06 / 23

Belite Bio Announces Submission to Swissmedic for Tinlarebant Phase 3 GA Clinical Trial in Switzerland

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 9 of 33

Belite Bio™ Inc
12750 High Bluff Drive Suite 475,
San Diego CA, 92130 USA

Join our mailing list.

Sign up to receive important updates and news from Belite Bio